The global Post-operative Pain Therapeutics market gathered revenue around USD 12.1 Bn billion in 2021 and market is set to grow USD 20.6 billion by the end of 2030 and is estimated to expand at a modest CAGR of 6.2% during the prediction period 2022 to 2030.
Growth Factors:
Increase in surgical procedures followed by post-surgical problems is anticipated to drive the global post-operative pain therapeutics market during the forecast period. Key players focus on manufacturing of cost-effective post-operative pain therapeutics. The global post-operative pain therapeutics market is expected to be driven by increase in the number of elderly patients, rise in prevalence of diseases, surge in number of regulatory approvals, and demand for post-operative pain therapeutics.
Asia Pacific held major share of the global post-operative pain therapeutics market in 2020 due to the presence of large number of key players, rise in demand for post-operative pain therapeutics, and increase in elderly patients. The post-operative pain therapeutics market in Asia Pacific is expected to expand at a CAGR of 6.7% from 2022 to 2030 owing to surge in number of elderly patients and increase in product approvals from regulatory authorities. This, in turn, is likely to drive the demand for post-operative pain therapeutics in emerging markets such as India and China.
Report Scope of the Post-operative Pain Therapeutics Market
Report Coverage |
Details |
Market Size |
US$ 20.6 Billion by 2030 |
Growth Rate |
CAGR of 6.2% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Drug Class, Route of Administration, Distribution Channel and Region, |
Companies Mentioned |
Allergan plc, Bayer AG, Camarus, Eli Lilly & Company, Egalet Corporation, Endo International plc, Janssen Pharmaceuticals, Inc., GlaxoSmithKline plc, Mallinckrodt Pharmaceuticals, Mylan N.V., Novartis AG, Pacira Pharmaceuticals, Inc., Pfizer, Inc., Purdue Pharma L.P, Teva Pharmaceutical Industries Ltd., and Trevena, Inc.. |
Advent of New Technology to Drive Global Market
The postoperative pain therapeutics market has witnessed significant investments by multinational corporates in the past few years. These business conglomerates have invested in companies operating in the postoperative pain therapeutics market. Camurus AB announced that the regulatory agency of Australia, the Therapeutic Goods Administration (TGA), approved key label updates to Buvidal Weekly and Buvidal Monthly (buprenorphine) modified-release solutions for injection for the treatment of opioid dependence.
Pacira BioSciences, Inc. received the FDA approval for its supplemental new drug application (sNDA) to broaden the use of EXPAREL (bupivacaine liposome injectable suspension) to include administration via interscalene brachial plexus block to produce postsurgical regional analgesia. Trevena announced FDA approval for OLINVYK (oliceridine) injection. OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic.
Pfizer, Inc. focuses on the development of biosimilar formulations in key therapeutic areas, owing to its potential to improve patient care by extending access to high quality, effective, and targeted treatment for multiple serious and chronic diseases.
Opioids Dominated Post-operative Pain Therapeutics Market
In terms of drug class, the global post-operative pain therapeutics market has been classified into opioids, NSAIDS, local anesthetics, tricyclic antidepressants, antiepileptic drugs, and others. The opioids segment dominated the global post-operative pain therapeutics market in 2020 and the trend is projected to continue during the forecast period. Increase in demand for opioids is expected to drive the segment over the next few years.
Oral Preferred Route of Administration
In terms of route of administration, the global post-operative pain therapeutics market has been categorized into oral, intramuscular, intravenous, and others. The oral segment dominated the global post-operative pain therapeutics market in 2020, and the trend is projected to continue during the forecast period.
Hospital Pharmacies to be Lucrative Distribution Channel
In terms of distribution channel, the global post-operative pain therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment held major share of the global post-operative pain therapeutics market in 2020.
Asia Pacific to Lead Global Market
In terms of region, the global post-operative pain therapeutics market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Asia Pacific is projected to account for leading share of the global post-operative pain therapeutics market during the forecast period, owing to increase in number of patients suffering from chronic diseases in hospitals. The post-operative pain therapeutics market in Asia Pacific is projected to grow at a rapid pace in the next few years. India, China, and South Korea are expected to be lucrative markets in the near future.
Some of the prominent players in the Post-operative Pain Therapeutics Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global Post-operative Pain Therapeutics Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Post-operative Pain Therapeutics Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Postoperative Pain Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Postoperative Pain Therapeutics Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.3. Pipeline Analysis
5.4. Regulatory Scenario, by Region/globally
5.5. Healthcare Industry Overview
6. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2030
6.3.1. Opioids
6.3.2. NSAIDS
6.3.3. Tricyclic Antidepressants
6.3.4. Antiepileptic Drugs
6.3.5. Local Anesthetics
6.3.6. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2030
7.3.1. Oral
7.3.2. Intravenous
7.3.3. Intramuscular
7.3.4. Others
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.3.4. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Postoperative Pain Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2030
10.2.1. Opioids
10.2.2. NSAIDS
10.2.3. Tricyclic Antidepressants
10.2.4. Antiepileptic Drugs
10.2.5. Local Anesthetics
10.2.6. Others
10.3. Market Value Forecast, by Route of Administration, 2017–2030
10.3.1. Oral
10.3.2. Intravenous
10.3.3. Intramuscular
10.3.4. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Postoperative Pain Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2030
11.2.1. Opioids
11.2.2. NSAIDS
11.2.3. Tricyclic Antidepressants
11.2.4. Antiepileptic Drugs
11.2.5. Local Anesthetics
11.2.6. Others
11.3. Market Value Forecast, by Route of Administration, 2017–2030
11.3.1. Oral
11.3.2. Intravenous
11.3.3. Intramuscular
11.3.4. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2030
11.5.1. U.K.
11.5.2. Germany
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Postoperative Pain Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2030
12.2.1. Opioids
12.2.2. NSAIDS
12.2.3. Tricyclic Antidepressants
12.2.4. Antiepileptic Drugs
12.2.5. Local Anesthetics
12.2.6. Others
12.3. Market Value Forecast By Route of Administration, 2017–2030
12.3.1. Oral
12.3.2. Intravenous
12.3.3. Intramuscular
12.3.4. Others
12.4. Market Value Forecast By Distribution Channel, 2017–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2030
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Postoperative Pain Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2017–2030
13.2.1. Opioids
13.2.2. NSAIDS
13.2.3. Tricyclic Antidepressants
13.2.4. Antiepileptic Drugs
13.2.5. Local Anesthetics
13.2.6. Others
13.3. Market Value Forecast, by Route of Administration, 2017–2030
13.3.1. Oral
13.3.2. Intravenous
13.3.3. Intramuscular
13.3.4. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Postoperative Pain Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2030
14.2.1. Opioids
14.2.2. NSAIDS
14.2.3. Tricyclic Antidepressants
14.2.4. Antiepileptic Drugs
14.2.5. Local Anesthetics
14.2.6. Others
14.3. Market Value Forecast, by Route of Administration, 2017–2030
14.3.1. Oral
14.3.2. Intravenous
14.3.3. Intramuscular
14.3.4. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.4.4. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix
15.2. Market Share Analysis, by Company, 2020
15.3. Competitive Business Strategies
15.4. Company Profiles
15.4.1. Mallinckrodt Pharmaceuticals
15.4.1.1. Company Description
15.4.1.2. Business Overview
15.4.1.3. Financial Overview
15.4.1.4. SWOT Analysis
15.4.2. Pfizer, Inc.
15.4.2.1. Company Description
15.4.2.2. Business Overview
15.4.2.3. Financial Overview
15.4.2.4. SWOT Analysis
15.4.3. Novartis AG
15.4.3.1. Company Description
15.4.3.2. Business Overview
15.4.3.3. Financial Overview
15.4.3.4. SWOT Analysis
15.4.4. Eli Lilly and Company
15.4.4.1. Company Description
15.4.4.2. Business Overview
15.4.4.3. Financial Overview
15.4.4.4. SWOT Analysis
15.4.5. Teva Pharmaceutical Industries Ltd.
15.4.5.1. Company Description
15.4.5.2. Business Overview
15.4.5.3. Financial Overview
15.4.5.4. SWOT Analysis
15.4.6. Camurus AB
15.4.6.1. Company Description
15.4.6.2. Business Overview
15.4.6.3. Financial Overview
15.4.6.4. SWOT Analysis
15.4.7. Bayer AG
15.4.7.1. Company Description
15.4.7.2. Business Overview
15.4.7.3. Financial Overview
15.4.7.4. SWOT Analysis
15.4.8. Pacira BioSciences, Inc.
15.4.8.1. Company Description
15.4.8.2. Business Overview
15.4.8.3. Financial Overview
15.4.8.4. SWOT Analysis
15.4.9. Trevena, Inc.
15.4.9.1. Company Description
15.4.9.2. Business Overview
15.4.9.3. Financial Overview
15.4.9.4. SWOT Analysis
15.4.10. Heron Therapeutics, Inc
15.4.10.1. Company Description
15.4.10.2. Business Overview
15.4.10.3. Financial Overview
15.4.10.4. SWOT Analysis